Inventor · disambiguated record
Oliver Ast
Also filed as: AST OLIVER
18 granted patents·21 pending applications·456 citations·filing 2002–2024
96Inventor score
Top patents by PatentIndex Score
39 records- 0198US11130822B2ImmunoconjugatesROCHE GLYCART AG·Filed 2019·Granted Sep 28, 2021·16 cites·24 claims
- 0298US10316104B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Jun 11, 2019·30 cites·23 claims
- 0398US10202464B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Feb 12, 2019·30 cites·3 claims
- 0498US10184009B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2017·Granted Jan 22, 2019·37 cites·30 claims
- 0598US9447159B2ImmunoconjugatesAST OLIVER·Filed 2012·Granted Sep 20, 2016·111 cites·27 claims
- 0697US10323098B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2016·Granted Jun 18, 2019·25 cites·30 claims
- 0797US9266938B2Mutant interleukin-2 polypeptidesAST OLIVER·Filed 2012·Granted Feb 23, 2016·123 cites·25 claims
- 0896US11111312B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2018·Granted Sep 7, 2021·8 cites·5 claims
- 0994US10683369B2Monoclonal antibodies against BCMAENGMAB SARL·Filed 2016·Granted Jun 16, 2020·14 cites·21 claims
- 1094US9914776B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted Mar 13, 2018·16 cites·42 claims
- 1192US11117965B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Granted Sep 14, 2021·2 cites·35 claims
- 1292US10611841B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·41 claims
- 1392US10611840B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·5 claims
- 1492US9963513B2Method for the selection of antibodies against BCMAENGMAB AG·Filed 2014·Granted May 8, 2018·19 cites·5 claims
- 1588US2025043028A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 1687US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 1787US2024141044A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1886US2024425616A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 1984US10077315B2Bispecific antibodies against CD3 and BCMAENGMAB AG·Filed 2014·Granted Sep 18, 2018·6 cites·5 claims
- 2084US2023340160A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 2184US2023287118A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2282US2022403027A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2380US10851171B2Method for the selection of antibodies against BCMAENGMAB SARL·Filed 2018·Granted Dec 1, 2020·1 cites·4 claims
- 2479US2022242971A1Novel immunoconjugatesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 2573US2023322957A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2022·Application pending·0 cites
- 2668US2021070873A1Method for the selection of antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 2767US2019322763A1Novel immunoconjugatesROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 2866US2019322765A1Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2019·Application pending·0 cites
- 2962US2018273643A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 3062US2020283545A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 3157US2013078249A1Bispecific t cell activating antigen binding moleculesAST OLIVER·Filed 2012·Application pending·0 cites
- 3256US2020255521A1Bispecific antibodies against cd3epsilon and ror1ENGMAB SARL·Filed 2020·Application pending·0 cites
- 3350US2016297881A1BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1ENGMAB AG·Filed 2014·Application pending·0 cites
- 3446US11952421B2Bispecific antibodies against CD3EPSILON and ROR1BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 9, 2024·0 cites·6 claims
- 3542US2003044961A1Compositions for transferring active compounds in a cell-specific mannerFiled 2002·Application pending·0 cites
- 3641US2013078250A1Bispecific t cell activating antigen binding moleculesAST OLIVER·Filed 2012·Application pending·0 cites
- 3738US2018282410A1Anti-cd3xrob04 bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3834US2017327579A1Bispecific antibodies against cd3epsilon and bcmaENGMAB AG·Filed 2015·Application pending·0 cites
- 3933US2017306044A1Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancerENGMAB AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Oliver Ast files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →